04 Aug 2025 Prepare to Order RSV Immunization for the 2025-2026 Season
Nirsevimab (Beyfortus) ordering will begin in August for the 2025-2026 season.
Nirsevimab (Beyfortus), a monoclonal antibody immunization used to prevent RSV infection in infants and young children, can be administered from October 1, 2025, to March 31, 2026.
The CDC plans to continue releasing nirsevimab (Beyfortus) through the VFC program in waves of limited amounts every two weeks based on estimated birth cohorts. While there will be ample supply to meet the needs of all VFC providers, each individual wave will provide limited doses. Therefore, initial ordering will be staggered to allow for all providers to have doses on hand when vaccine administration begins on October 1, 2025.
Next Steps
- Your office will be contacted via email with a specific timeframe and amount that you are permitted to order.
- Do not attempt to order outside of your timeframe. Orders placed outside your timeframe will be rejected.
- Our ordering team may adjust order thresholds to ensure an adequate and equitable distribution of available doses throughout the City.
- If you do not order during your assigned wave, you may order again when ordering starts on Monday, September 15, 2025.
- Ensure that your contact information is up to date in PhilaVax and that you check your email regularly for updates.
Contact our VFC Coordinator, Alisha Conway, at alisha.conway@phila.gov, or our ordering team at dphproviderhelp@phila.gov with any questions.
Eligibility, Dosage, & Administration
Nirsevimab is administered as an intramuscular injection with a single-dose, pre-filled syringe, and it should be ordered to be properly administered by weight.
Indications:
- Infants aged < 8 months born during or entering their first RSV season
- 50 mg for infants weighing < 5 kg
- 100 mg for infants weighing ≥ 5 kg
- Children 8-19 months who are at increased risk of severe RSV disease and are entering their second RSV season
- 200 mg, administered as two 100 mg injections
Click here to view more information about which children are at increased risk and should be vaccinated during their second season.
Click here to view a flowchart to aid providers in determining the appropriate dose of nirsevimab (Beyfortus) for patients.
Storage & Handling
- Store refrigerated between 36°F to 46°F (2°C to 8°C) through the expiration date.
- After removal from the refrigerator, nirsevimab must be used within 8 hours or discarded.
Reporting Adverse Events
Nirsevimab is the first drug product to be included in the VFC program. If nirsevimab is administered:
- alone, suspected adverse events are reported to MedWatch.
- simultaneously with any vaccine, suspected adverse events are reported to the Vaccine Adverse Event Reporting System (VAERS).
- Additional reporting to MedWatch is not needed.